
|Videos|August 3, 2020
Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation (ASRS 2020)
Author(s)Alex Delaney-Gesing , David Hutton
Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."
Advertisement
Daniel F. Kiernan, MD, FACS, speaks with Ophthalmology Times®' David Hutton on the key findings and take-aways from his presentation, "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery," during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves NDA labeling supplement allowing re-administration of iDose TR
2
Opus Genetics launches phase 1/2 MERTK gene therapy trial
3
Dr. Mali’s top 5 predictions in ophthalmology for 2026
4
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
5



























